



**Direct Access to Functionalized Benzotropones, Azepanes,  
and Piperidines by Reductive Cross-Coupling of Alpha-  
Bromo Enones with Alpha-Bromo Eneformamides or  
Enecarbamates**

Journal:	<i>Organic &amp; Biomolecular Chemistry</i>
Manuscript ID:	OB-COM-03-2015-000517.R1
Article Type:	Communication
Date Submitted by the Author:	02-Apr-2015
Complete List of Authors:	Beng, Timothy; Susquehanna University, Chemistry Sincavage, Kayla; Susquehanna University, Chemistry Silaire, Ann Wens; Susquehanna University, Chemistry Alwali, Amir; Susquehanna University, Chemistry Bassler, Daniel; Susquehanna University, Chemistry Spence, Laura; Susquehanna University, Chemistry Beale, Oliver; Susquehanna University, Chemistry

## Communication

# Direct Access to Functionalized Benzotropones, Azepanes, and Piperidines by Reductive Cross-Coupling of Alpha-Bromo Enones with Alpha-Bromo Eneformamides or Encarbamates

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012,  
Accepted 00th January 2012


DOI: 10.1039/x0xx00000x

www.rsc.org/

Timothy K. Beng,\* Kayla Sincavage, Ann Wens V. Silaire, Amir Alwali, Daniel P. Bassler, Laura E. Spence, and Oliver Beale

The synthesis of functionalized azepenes and piperidines bearing an  $\alpha$ -cycloheptenone or benzotropone derivative has been accomplished through direct reductive cross-coupling of  $\alpha$ -bromo eneformamides or encarbamates with highly versatile  $\alpha$ -bromo benzotropone derivatives, under cobalt catalysis. The coupling products have been further elaborated to other synthetically useful aza-heterocyclic frameworks.

Functionalized benzotropones, cycloheptenones, azacycloheptanes (*i.e.*, azepanes), and azacyclohexanes (*i.e.*, piperidines) are ubiquitous structural motifs in bioactive natural products and pharmaceuticals including perovskatone A (from *Perovskia atriplicifolia*, Fig. 1),<sup>1</sup> colchicine (from *Colchicum autumnale*),<sup>2</sup> longeraciphyllin B (from *Daphniphyllum yunnanense*),<sup>3</sup> stenine (from *Stemona tuberosa*), and nominine (from *Aconitum sanyoense*).<sup>4</sup>






**Fig. 1** Examples of functionalized tropone, cycloheptenone, azepane, and piperidine alkaloids and pharmaceuticals

Fittingly, key features such as structural diversity and biological relevance continue to inspire researchers toward developing



increasingly more efficient strategies for the construction and functionalization of (benzo)tropane,<sup>5</sup> cycloheptenone,<sup>6</sup> azepane,<sup>7-9</sup> and piperidine<sup>9-13</sup> derivatives. If two or more of the aforementioned motifs are coupled together, it is recognized that the structural space for the discovery of novel scaffolds with medicinal value would be greatly expanded. The conventional cross-coupling of nucleophilic coupling partners such as vinyl stannanes and aryl boronic acids (see **I**, Fig. 2A) with  $\alpha$ -halo enones such as **II** has previously been accomplished under forcing conditions.<sup>14</sup> Given the now established reactivity series of  $\alpha$ -halo enones relative to the unsubstituted counterpart (Fig. 2B),<sup>15</sup> conventional cross-coupling strategies featuring the latter, under less forcing conditions, have subsequently emerged.<sup>16</sup> Our interest in functionalized azaheterocycles<sup>11, 12, 17, 18</sup> led us to the discovery that  $\alpha$ -halo eneformamides such as **IV** may be satisfactorily coupled with aryl, alkenyl, and alkynyl nucleophiles.<sup>7, 18</sup> Very recently, we have disclosed that cyclic  $\alpha$ -bromo eneformamides and encarbamates are amenable to cobalt-catalyzed reductive cross-coupling with aryl or vinyl bromides (Fig. 2C).<sup>19</sup> In this umpolung process, the catalyst (rather than the substrate) is reduced, thus, obviating the need for the pregeneration of difficult-to-handle, expensive, or toxic organometallic reagents. Seeking an efficient strategy that would provide access to functionalized azaheterocycles bearing a benzotropone derivative (Fig. 2D) or a  $\beta$ -amino substituent (Fig. 2E), we reasoned that direct reductive cross-coupling of two readily available, stable, and easy to handle electrophilic organic bromides, under transition metal-catalysis, offered an attractive approach.<sup>20</sup> Communicated herein, are our current efforts toward the realization of the proposed plan.

Our studies on the reductive cross-coupling of  $\alpha$ -bromo enones (examples of which are depicted in Fig. 3) with  $\alpha$ -bromo eneformamides and encarbamates commenced with the search for the best phosphine-based ligand and transition metal catalyst.

## previous work:




## this work:



**Fig. 2** Proposed plan for accessing functionalized azaheterocycles containing at least one cycloheptenone derivative




Cognizant of the high tolerance for carbonyl-containing functional groups in reductive cross-couplings and hoping to apply some of the lessons learned from our recent report on Co-catalyzed cross-coupling of bromo enamides with bromoarenes<sup>19</sup> to the current scenario, we were pleased to find that the coupling of bromo enecarbamate **10** with bromo enone **1** proceeds efficiently at room temperature using the conditions described in Scheme 1A (see **13**).



**Fig. 3** Selected enone derivatives employed in these studies

As a testament to the generality of the transformation, methoxy-bearing bromo enone **2** and chlorine-containing enone **3** both furnish the  $\alpha$ -vinylated adducts in good yield (see **14** & **15**). This is noteworthy, since either substituent (*i.e.*, the methoxy or chlorine substituent) could serve as a place-holder or functional handle for

late-stage diversification. The marginal increase in the efficacy and rate of coupling of **2** with **10** suggests that electron-rich bromo enones have a beneficial effect on the transformation. This is somewhat understandable given the general reactivity of  $\alpha$ -halo enones (see Fig. 2B). Encouragingly, despite being less stable and enolizable, bromo enone **4** still couples with bromo enecarbamate **10**, affording imino diene **16** in acceptable yield, following acid-mediated cleavage of the Boc-group. The importance of having a benzannulated bromo enone (which aids to slow down reactivity, thus, mitigating undesirable homocoupling) is supported by the observation that the reaction of  $\alpha$ -bromocycloheptenone **5** with bromo enecarbamate **10** affords mostly the homocoupling product, even when the former is introduced slowly over the course of an hour. Consistent with our previous findings on the superiority of bromo eneforamidate **11** (relative to bromo enecarbamate **10**) as a coupling partner in reductive cross-couplings,<sup>19</sup> we find that it couples modestly with **5** (see **17**).




**Scheme 1** Co-catalyzed reductive cross-coupling of  $\alpha$ -bromo enones with organic bromides

As further illustrated in Scheme 1A, azepane-derived bromo eneforamidate **12** is also amenable to Co-catalyzed reductive cross-coupling with  $\alpha$ -bromo enones (see **18–20**). Understandably (especially from a stability standpoint), dibromonaphthoquinone **6** couples inefficiently with **10** under the identified conditions (Scheme 1B). These studies have also revealed that highly versatile  $\alpha$ -bromo

enaminones such as **7**, **8**, or **9** undergo satisfactory Co-catalyzed cross-electrophile-coupling with bromo styrenes, bromo acrylates, bromoarenes, and allylic bromides (Scheme 1C). The latter example (*i.e.*, formation of **25**) features net regioselective  $\beta$ -allylation of an enaminone. This is noteworthy since the presence of an allyl moiety on a piperidine skeleton offers several advantages for the synthesis of piperidine alkaloids and pharmaceuticals. For example, as has been demonstrated for 2-allyl piperidine derivatives, the double bond on the allyl moiety can be reduced,<sup>11, 21</sup> oxidized,<sup>11, 22</sup> engaged in metathesis reactions,<sup>13</sup> or carbolithiated.<sup>23</sup>

Desiring to broaden the synthetic utility of the reductive coupling methodology described herein, we have shown that further elaboration of the coupling products depicted in Scheme 1 to other synthetically important molecular architectures is possible. For example, chemoselective reduction of the double bond resident in the allyl moiety of allylated enaminone **26** (prepared in the same way as **25**, see Scheme 1C) affords  $\beta$ -alkylated derivative **27** in high yield, without any complications arising from benzonolysis, conjugate, or 1,2-reduction of the enaminone motif (Scheme 2A). Additionally, *N*-acyl iminium reduction of *N*-formyl amino diene **17** affords piperidine derivative **28** (Scheme 2B). Furthermore, cleavage of the Boc-group in **14** quantitatively furnishes  $\alpha$ -functionalized cyclic imine **29** (not shown), which upon subjection to sequential  $\alpha$ -acylation and  $\alpha$ -methylation of the corresponding aza-enolate, affords 3,3-difunctionalized 1,2-dehydropiperidine **30** in 59% overall yield (Scheme 2C). In another significant outcome, we have found that electronically frustrated imino dienes such as **31** (obtained from **18**, see Scheme 1A) are amenable to a [4 + 2] cycloaddition with activated dienophiles such as ester quinone **32**. For example, treatment of **31** with **32** under thermal conditions affords highly functionalized pentacycle **33** (Scheme 2D). Primarily due to challenges associated with stability, the relative configuration of **33** hasn't been unambiguously established at this point.



**Scheme 2** Elaboration of reductive coupling products to other functionalized azaheterocycles

## Conclusions

In summary, the cobalt-catalyzed reductive cross-coupling of versatile  $\alpha$ -bromo enones with cyclic  $\alpha$ -bromo enamides has been accomplished under mild conditions. The 2-substituted benzotroponone and cycloheptenone derivatives are amenable to further functionalization under different modes of reactivity, including chemoselective catalytic hydrogenation, *N*-acyl iminium reduction, [4 + 2]-cycloaddition, and  $\alpha$ -acylation/methylation. These short synthetic sequences set the stage for the synthesis of functionalized piperidine or azepane alkaloids and pharmaceuticals bearing a benzotroponone derivative, details of which will be disclosed later.

## Acknowledgments

We are grateful to the Chemistry Department and the Committee for Faculty Scholarship at Susquehanna University for funding. Professor Bill Dougherty is greatly acknowledged for making it logistically possible for us to perform experiments involving air- and moisture-sensitive reagents at SU. T.K.B. is particularly thankful to Miss Sarah Pursley Beng for some strategic comments during the incipient stages of this project.

## Notes and references

<sup>a</sup> Department of Chemistry, Susquehanna University, 514 University Avenue, Selinsgrove, PA 17870, USA. \*[beng@susqu.edu](mailto:beng@susqu.edu).

Electronic Supplementary Information (ESI) available: Experimental procedures and spectroscopic data. See DOI: 10.1039/c000000x/

- Z.-Y. Jiang, C.-G. Huang, H.-B. Xiong, K. Tian, W.-X. Liu, Q.-F. Hu, H. B. Wang, G.-Y. Yang and X.-Z. Huang, *Tetrahedron Lett.*, 2013, **54**, 3886.
- M. J. S. Dewar, *Nature*, 1945, **155**, 141.
- H. Zhang, S.-P. Yang, C.-Q. Fan, J. Ding and J.-M. Yue, *J. Nat. Prod.*, 2006, **69**, 553.
- S. Sakai, I. Yamamoto, K. Yamaguchi, H. Takayama, M. Ito and T. Okamoto, *Chem. Pharm. Bull.*, 1982, **30**, 4579.
- (a) U. Albrecht, H. Armbrust and P. Langer, *Synlett*, 2004, 143; (b) J. K. Laha, *Lett. Org. Chem.*, 2007, **4**, 550; *Chem. Nat. Compd.*, 2010, **46**, 254; (c) M. Majewski and R. Lazny, *Synlett*, 1996, 785.
- (a) N. B. Bennett, A. Y. Hong, A. M. Harned and B. M. Stoltz, *Org. Biomol. Chem.*, 2012, **10**, 56; (b) Y. L. Choi, C.-M. Yu, B. T. Kim and J.-N. Heo, *J. Org. Chem.*, 2009, **74**, 3948; (c) N. Germain, D. Schlaefli, M. Chellat, S. Rosset and A. Alexakis, *Org. Lett.*, 2014, **16**, 2006; (d) A. Y. Hong, N. B. Bennett, M. R. Krout, T. Jensen, A. M. Harned and B. M. Stoltz, *Tetrahedron*, 2011, **67**, 10234; (e) S. Y. Kim, S. I. Lee, S. Y. Choi and Y. K. Chung, *Angew. Chem., Int. Ed.*, 2008, **47**, 4914; (f) M. Leiva de Faria, R. d. A. Magalhaes, F. C. Silva, L. G. d. O. Matias, M. A. Ceschi, U. Brocksom and T. J. Brocksom, *Tetrahedron Asymmetry*, 2000, **11**, 4093; (g) Y. Nakai, M. Kawahata, K. Yamaguchi and K. Takeda, *J. Org. Chem.*, 2007, **72**, 1379; (h) Y. Oonishi, M. Mori and Y. Sato, *Synthesis*, 2007, 2323; (i) C. S. Pak and S. K. Kim, *J. Org. Chem.*, 1990, **55**, 1954; (j) Y. Sato, Y. Oonishi and M. Mori, *Angew. Chem., Int. Ed.*, 2002, **41**, 1218; (k) M. R. J. Vallee, I. Inhuelsen and P. Margaretha, *Helv. Chim. Acta*, 2010, **93**, 17; (l) P. A. Wender, A. J. Dyckman, C. O. Husfeld and M. J. C. Scanio, *Org. Lett.*, 2000, **2**, 1609; (m) P. A. Wender, L. E. Sirois, R. T. Stemmler and T. J. Williams, *Org. Lett.*, 2010, **12**, 1604.
- T. K. Beng, S. M. Wilkerson-Hill and R. Sarpong, *Org. Lett.*, 2014, **16**, 916.
- (a) E. Denmark Scott and M. Xie, *J. Org. Chem.*, 2007, **72**, 7050; (b) J. Lee Suk and P. Beak, *J. Am. Chem. Soc.*, 2006, **128**, 2178; (c) H. Li, Y. Bleriot, C. Chantereau, J.-M. Mallet, M. Sollogoub, Y. Zhang, E. Rodriguez-Garcia, P. Vogel, J. Jimenez-Barbero and P. Sinay, *Org. Biomol. Chem.*, 2004, **2**, 1492; (d) D. P. S. Macfarlane, D. Norton, R. J. Whitby and D. Tupper, *Synlett*, 2006, 3439; (e) M. Mondon, F. Lecornue, J. Guillard, S. Nakagawa, A. Kato and Y. Bleriot, *Bioorg. Med. Chem.*, 2013, **21**, 4803; (f) T.-L. Shih, M.-T. Liang, K.-D. Wu and C.-H. Lin, *Carbohydr. Res.*, 2011,

- 346, 183.
- 9 J. Dolfen, S. Kenis, K. Van Hecke, N. De Kimpe and M. D'Hooghe, *Chem. - Eur. J.*, 2014, **20**, 10650.
- 10 (a) I. Abrunhosa-Thomas, A. Plas, A. Vogrig, N. Kandepedu, P. Chalard and Y. Troin, *J. Org. Chem.*, 2013, **78**, 2511; (b) E. Airiau, N. Girard, M. Pizzeti, J. Salvadori, M. Taddei and A. Mann, *J. Org. Chem.*, 2010, **75**, 8670; (c) G. Arena, N. Zill, J. Salvadori, N. Girard, A. Mann and M. Taddei, *Org. Lett.*, 2011, **13**, 2294; (d) J. M. Aurecochea, J. M. Gorgojo and C. Saornil, *Synthesis*, 2010, 605; (e) T. K. Beng and N. Fox, *Tetrahedron Lett.*, 2015, **56**, 119; (f) G. J. Brizgys, H. H. Jung and P. E. Floreancig, *Chem. Sci.*, 2012, **3**, 438; (g) E. J. Cochrane, D. Leonori, L. A. Hassall and I. Coldham, *Chem. Commun.*, 2014, **50**, 9910; (h) N. Coia, N. Mokhtari, J.-L. Vasse and J. Szymoniak, *Org. Lett.*, 2011, **13**, 6292; (i) X. Companyo, A.-N. Alba and R. Rios, *Targets Heterocycl. Syst.*, 2009, **13**, 147; (j) S. G. Davies, A. M. Fletcher, D. G. Hughes, J. A. Lee, P. D. Price, P. M. Roberts, A. J. Russell, A. D. Smith, J. E. Thomson and O. M. H. Williams, *Tetrahedron*, 2011, **67**, 9975; (k) A. A. Fesenko and A. D. Shutalev, *Tetrahedron Lett.*, 2012, **53**, 6261; (l) N. Gouault, M. Le Roch, A. Cheignon, P. Uriac and M. David, *Org. Lett.*, 2011, **13**, 4371; (m) J. Han, B. Xu and G. B. Hammond, *Org. Lett.*, 2011, **13**, 3450; (n) K. D. Hesp, D. P. Fernando, W. Jiao and A. T. Londregan, *Org. Lett.*, 2014, **16**, 413; (o) M. Jaekel, J. Qu, T. Schnitzer and G. Helmchen, *Chem. - Eur. J.*, 2013, **19**, 16746; (p) S. B. D. Jarvis and A. B. Charette, *Org. Lett.*, 2011, **13**, 3830; (q) L. I. Kas'yan, V. A. Pal'chikov and Y. S. Bondarenko, *Russ. J. Org. Chem.*, 2011, **47**, 1609; (r) Y. Li, Z. Xue, W. Ye, J. Liu, J. Yao and C. Wang, *ACS Comb. Sci.*, 2014, **16**, 113; (s) H. Liu, D. Su, G. Cheng, J. Xu, X. Wang and Y. Hu, *Org. Biomol. Chem.*, 2010, **8**, 1899; (t) A. Millet, P. Larini, E. Clot and O. Baudoin, *Chem. Sci.*, 2013, **4**, 2241; (u) S. Mizuta and O. Onomura, *RSC Adv.*, 2012, **2**, 2266; (v) P. R. Payne, P. Garcia, P. Eisenberger, J. C. H. Yim and L. L. Schafer, *Org. Lett.*, 2013, **15**, 2182; (w) G. Pelletier, L. Constantineau-Forget and B. Charette Andre, *Chem Commun*, 2014, **50**, 6883; (x) A. Peschiulli, V. Smout, T. E. Storr, E. A. Mitchell, Z. Elias, W. Herrebout, D. Berthelot, L. Meerpoel and B. U. W. Maes, *Chem. - Eur. J.*, 2013, **19**, 10378; (y) M. Potowski, J. O. Bauer, C. Strohmann, A. P. Antonchick and H. Waldmann, *Angew. Chem., Int. Ed.*, 2012, **51**, 9512; (z) M. Potowski, A. P. Antonchick and H. Waldmann, *Chem. Commun.*, 2013, **49**, 7800.
- 11 (a) T. K. Beng and R. E. Gawley, *J. Am. Chem. Soc.*, 2010, **132**, 12216; (b) *Heterocycles*, 2012, **84**, 697.
- 12 T. K. Beng, J. S. Woo and R. E. Gawley, *J. Am. Chem. Soc.*, 2012, **134**, 14764.
- 13 G. Cheng, X. Wang, D. Su, H. Liu, F. Liu and Y. Hu, *J. Org. Chem*, 2010, **75**, 1911.
- 14 (a) X. Wang, B. J. Turunen, M. W. Leighty and G. I. Georg, *Tetrahedron Lett.*, 2007, **48**, 8811; (b) D. L. Comins, S. P. Joseph and X. Chen, *Tetrahedron Lett.*, 1995, **36**, 9141.
- 15 K. Li and A. Alexakis, *Angew. Chem., Int. Ed.*, 2006, **45**, 7600.
- 16 (a) H. Ge, M. J. Niphakis and G. I. Georg, *J. Am. Chem. Soc.*, 2008, **130**, 3708; (b) Y. W. Kim, M. J. Niphakis and G. I. Georg, *J. Org. Chem.*, 2012, **77**, 9496; (c) Y. W. Kim and G. I. Georg, *Org. Lett.*, 2014, **16**, 1574; (d) H. Seki and G. I. Georg, *Synlett*, 2014, **25**, 2536; (e) Y.-Y. Yu, M. J. Niphakis and G. I. Georg, *Org. Lett.*, 2011, **13**, 5932; (f) Y.-Y. Yu, L. Bi and G. I. Georg, *J. Org. Chem.*, 2013, **78**, 6163.
- 17 (a) T. K. Beng and R. E. Gawley, *Org. Lett.*, 2011, **13**, 394; (b) T. K. Beng, W. S. Tyree, T. Parker, C. Su, P. G. Williard and R. E. Gawley, *J. Am. Chem. Soc.*, 2012, **134**, 16845; (c) I. Coldham, D. Leonori, T. K. Beng and R. E. Gawley, *Chem. Commun.*, 2009, 5239; (d) T. K. Beng, T. I. Yousaf, I. Coldham and R. E. Gawley, *J. Am. Chem. Soc.*, 2009, **131**, 6908; (e) D. P. Bassler, L. Spence, A. Alwali, O. Beale and T. K. Beng, *Org. Biomol. Chem.*, 2015, **13**, 2285.
- 18 T. K. Beng and D. P. Bassler, *Tetrahedron Lett.*, 2014, **55**, 6662.
- 19 D. P. Bassler, A. Alwali, L. Spence, O. Beale and T. K. Beng, *J. Organomet. Chem.*, 2015, **780**, 6.
- 20 (a) A. H. Cherney and S. E. Reisman, *J. Am. Chem. Soc.*, 2014, **136**, 14365; (b) W. M. Czaplak, M. Mayer and A. J. von Wangelin, *ChemCatChem*, 2011, **3**, 135; (c) D. A. Everson, R. Shrestha and D. J. Weix, *J. Am. Chem. Soc.*, 2010, **132**, 920; (d) D. A. Everson, B. A. Jones and D. J. Weix, *J. Am. Chem. Soc.*, 2012, **134**, 6146; (e) C. E. I. Knappke, S. Grupe, D. Gaertner, M. Corpet, C. Gosmini and A. Jacobi von Wangelin, *Chem. - Eur. J.*, 2014, **20**, 6828; (f) X. Lu, J. Yi, Z.-Q. Zhang, J.-J. Dai, J.-H. Liu, B. Xiao, Y. Fu and L. Liu, *Chem. - Eur. J.*, 2014, **20**, 15339; (g) G. A. Molander, S. R. Wisniewski and K. M. Traister, *Org. Lett.*, 2014, **16**, 3692; (h) Q. Qian, Z. Zang, S. Wang, Y. Chen, K. Lin and H. Gong, *Synlett*, 2013, **24**, 619; (i) Q. Ren, F. Jiang and H. Gong, *J. Organomet. Chem.*, 2014, **770**, 130; (j) H. Xu, C. Zhao, Q. Qian, W. Deng and H. Gong, *Chem. Sci.*, 2013, **4**, 4022; (k) C.-S. Yan, Y. Peng, X.-B. Xu and Y.-W. Wang, *Chem. - Eur. J.*, 2012, **18**, 6039; (l) Y. Yang, K. Niedermann, C. Han and S. L. Buchwald, *Org. Lett.*, 2014, **16**, 4638; (m) X. Yu, T. Yang, S. Wang, H. Xu and H. Gong, *Org. Lett.*, 2011, **13**, 2138.
- 21 H. Takahata, H. Ouchi, M. Ichinose and H. Nemoto, *Org. Lett.*, 2002, **4**, 3459.
- 22 (a) L.-H. Yan, F. Dagorn, E. Gravel, B. Seon-Meniél and E. Poupon, *Tetrahedron*, 2012, **68**, 6276; (b) H. Takahata, M. Kubota, S. Takahashi and T. Momose, *Tetrahedron Asymmetry*, 1996, **7**, 3047; (c) M. Kavala, F. Mathia, J. Kozišek and P. Szolcsanyi, *J. Nat. Prod.*, 2011, **74**, 803; (d) S. Freville, P. Delbecq, V. M. Thuy, H. Petit, J. P. Celerier and G. Lhommet, *Tetrahedron Lett.*, 2001, **42**, 4609.
- 23 (a) M. Yus and R. Ortiz, *Eur. J. Org. Chem.*, 2004, 3833; (b) Y. Tomida, A. Nagaki and J.-i. Yoshida, *J. Am. Chem. Soc.*, 2011, **133**, 3744; (c) N. J. Ashweek, I. Coldham, D. J. Snowden and G. P. Vennall, *Chem. Eur. J.*, 2002, **8**, 195; (d) I. Coldham, R. Hufton, K. N. Price, R. E. Rathmell, D. G. Snowden and G. P. Vennall, *Synthesis*, 2001, 1523.